The influence of a combined low dose oral contraceptive containing drospirenone on electrolite equlibrum and renal function in young woman

被引:0
作者
Szlendak-Sauer, Katarzyna [1 ]
Radowicki, Stanislaw [1 ]
Skorzewska, Katarzyna [1 ]
机构
[1] WUM, Klin Endokrynol Ginekol, PL-00315 Warsaw, Poland
关键词
contraception; drospirenone; electrolytes; renal function; RENIN-ALDOSTERONE SYSTEM; PROGESTOGEN;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Drospirenone - a new 17 alpha-spironolactone derivate is a progestin with aldosterone receptor antagonism activity (PARA) thanks to which it decreases sodium and fluid retention. The aim: The aim of our study was to estimate the electrolytes level and renal function parameters in blood during the therapy of low dose oral contraceptive containing drospirenone. Material and methods: The group consisted of 22 young women in mean age 25,9 4,3 years, without contraindications to hormonal contraception used specimen containing 20 mu g ethinyloestradial and 3.0mg drospirenone during 12 cycles. Blood levels of electrolytes (sodium, potassium, calcium, phosphorus and chloride) and renal function parameters (creatinine, urea and uric acid) were evaluated before and after 3, 6 and 12 cycles of the treatment. Results: There were no statistically significant differences observed in serum concentration of electrolytes and renal function parameters. Conclusion: The therapy of a low dose oral contraceptive containing 20 mu g ethinyloestradiol and 3.0mg drospirenone does not influence the electrolyte equilibrium and renal function.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 14 条
[1]   Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms [J].
Apter, D ;
Borsos, A ;
Baumgärtner, W ;
Melis, GB ;
Vexiau-Robert, D ;
Colligs-Hakert, A ;
Palmer, M ;
Kelly, S .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2003, 8 (01) :37-51
[2]  
BARANOWSKI W, 2003, PRZ MENOPAUZALNY, V2, P12
[3]   Hormonal contraception update [J].
David, PS ;
Boatwright, EA ;
Tozer, BS ;
Verma, DP ;
Blair, JE ;
Mayer, AP ;
Files, JA .
MAYO CLINIC PROCEEDINGS, 2006, 81 (07) :949-955
[4]   Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes [J].
Eng, Patricia Mona ;
Seeger, John D. ;
Loughlin, Jeanne ;
Oh, Kelly ;
Walker, Alexander M. .
CONTRACEPTION, 2007, 75 (02) :101-107
[5]   Drospirenone and its antialdosterone properties [J].
Genazzani, A. R. ;
Mannella, P. ;
Simoncini, T. .
CLIMACTERIC, 2007, 10 :11-18
[6]   Drospirenone: pharmacology and pharmacokinetics of a unique progestogen [J].
Krattenmacher, R .
CONTRACEPTION, 2000, 62 (01) :29-38
[7]   EFFECTS OF A NEW ORAL-CONTRACEPTIVE CONTAINING ARM ANTIMINERALOCORTICOID PROGESTOGEN, DROSPIRENONE, ON THE RENIN-ALDOSTERONE SYSTEM, BODY-WEIGHT, BLOOD-PRESSURE, GLUCOSE-TOLERANCE, AND LIPID-METABOLISM [J].
OELKERS, W ;
FOIDART, JM ;
DOMBROVICZ, N ;
WELTER, A ;
HEITHECKER, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (06) :1816-1821
[8]   Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers [J].
Oelkers, W ;
Helmerhorst, FM ;
Wuttke, W ;
Heithecker, R .
GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (03) :204-213
[9]   Drospirenone, a progestogen with antimineralocorticoid properties: a short review [J].
Oelkers, W .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 217 (1-2) :255-261
[10]  
Oelkers W, 2002, EUR J CONTRACEP REPR, V7, P19